Lead Product(s): Antibody-drug conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Apricot Capital
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 01, 2021
The series A financing will help in accelerating Medilink's innovative pipeline development and to support its unique conjugate technology platform.